Drugs Made in America AcquisDMAAU
13F holders, Q1 2026 (March 31)2holders −3
0new positions
2sold out
$10.50avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Drugs Made in America Acquis (DMAAU) in their 13F filings, down 3 from Q4 2025. 0 opened new positions and 2 sold out. The largest holders were Clear Street Group Inc. ($105K) and UBS Group AG ($16K).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2847J120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $1.7M |
All 13F filers, Q4 2025 → Q1 2026: 247,719 shares sold, net −247,719 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Clear Street Group Inc. | 0.00% | Reduce -89.0% | 10,000 | $105K |
| UBS Group AG | 0.00% | Reduce -81.0% | 1,521 | $16K |
"% of holder's portfolio" is DMAAU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.